- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05030363
ALDH Enzyme in CRF With Advanced GI Cancer (ALDHCRF)
December 24, 2021 updated by: Korea University Anam Hospital
The Efficacy and Safety of Alcoholic Dehydrogenase (ALDH) Enzyme Supplement in Chemotherapy-Related Fatigue With Advanced Gastrointestinal Cancer Patients: A 2-Period, Crossover, Single-Center Study
Aldehyde dehydrogenase (ALDH) enzyme supplementation plays an essential role in the elimination of toxic metabolites and reduction of reactive oxygen species bioactivation, which can protect and relieve chemotherapy-related fatigue (CRF) in cancer patients.
The aim of this study is to evaluate the efficacy and safety of ALDH enzyme in CRF with advanced gastrointestinal cancer patients.
The primary endpoint is the change of FACIT-F (Functional Assessment of Chronic Illness Therapy-Fatigue) score on day 15 compared to baseline after chemotherapy.
The secondary endpoint including change of FACIT-F on day 29 compared to day 15, change of ESAS (Edmonton Symptom Assessment System) on day 15 compared to baseline, safety and toxicities, and exploratory biomarkers.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Chemotherapy-related fatigue (CRF) occurs universally in cancer patients which can be a debilitating symptom that affects patients' quality of life.
The impact of CRF has been associated with mood disorder, sleep disturbance, cognitive dysfunction, inflammation mediated putative biological disturbances, and functional morbidities.
Although the etiology is heterogeneous and complex, one of the proposed mechanisms is that chemotherapy induced multiple oxidative degradation of the lipid membrane which generates reactive oxygen species (ROS) and tissue damage.
These conditions result in inflammation-induced reduction in central dopaminergic neurotransmission, nutritional deficiency (especially in vitamins and minerals), and immunodeficiency, which clinically manifest as CRF.
To date, various agents including psychostimulants (methylphenidate, donepezil, and modafinil), dexamethasone, and Korean red ginseng (KRG) were used in the management of CRF.
However, the prevalence of CRF is still high primarily due to lack of proven effective therapies.
ALDH enzyme supplementation plays an essential role in the eliminates 4-hydoxynonenal, malondialdehyde from lipid peroxidation and reduce ROS bioactivation, which can protect and relieve CRF in cancer patients.
Based on these rational backgrounds, the aim or this study is to evaluate the efficacy and safety of ALDH enzyme in CRF with advanced gastrointestinal cancer patients.
Study Type
Interventional
Enrollment (Anticipated)
82
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Soohyeon Lee, M.D., Ph.D.
- Phone Number: 82-2-920-5690
- Email: soohyeon_lee@korea.ac.kr
Study Locations
-
-
-
Seoul, Korea, Republic of, 02841
- Recruiting
- Korea University Anam Hospital
-
Contact:
- Soohyeon Lee, M.D., Ph.D.
- Email: soohyeon_lee@korea.ac.kr
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 100 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
To be included in the trial, subjects must meet all of the following criteria:
- Fatigue score ≥ 4 on analog scale of 0 to 10 (0; not at all, 10; worst possible fatigue) for more than 1 week.
- Subject has willing and able to written informed consent form (ICF) prior to any screening procedures.
- Age ≥ 19 years old of male and female.
- Life expectancy more than 3 months.
Exclusion Criteria:
- Hb < 8g/dL
- Uncontrolled hyper- or hypothyroidism despite of appropriate treatment
- Evidence of central nervous system (CNS) tumor metastasis; permitted if asymptomatic or neurologically stable.
- Sign of active and uncontrolled bacterial or viral infection requiring systemic therapy
- Abnormal cognition status or psychiatric disease.
- Anamnesis of hypersensitivity reaction to the ALDH enzyme.
- Current use or previous use within 14 days of the following medications: Korean-Chinese medications, methylphenidate, modafinil, phenobarbital, diphenylhydantoin, primidone, phenylbutazone, monoamine oxidase inhibitors, clonidine, and tricyclic antidepressants.
- Medical conditions that could affect trial outcomes or subjects who were considered unsuitable for trial enrollment by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Upfront ALDH enzyme supplement
Upfront ALDH enzyme supplement; After randomization, patients will receive ALDH enzyme supplement twice a day for consecutive 14 days during chemotherapy (period 1; day 1 to day 14) until unacceptable toxicity, or consent withdrawal.
Patients will visit clinic on day 15, then will be followed on day 29 without ALDH enzyme administration during subsequent chemotherapy (period 2).
|
ALDH enzyme (PICOZYMEQ™)
|
Other: Delayed ALDH enzyme supplement
Delayed ALDH enzyme supplement; patients will not take ALDH enzyme supplement during chemotherapy after randomization on day 1 to day 14 (period 1).
On day 15, Patients will visit for subsequent chemotherapy and start ALDH enzyme supplement twice a day for 14 consecutive days during chemotherapy (period 2; day 15 to day 29).
|
ALDH enzyme (PICOZYMEQ™)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of FACIT-F score
Time Frame: Day 15 compared to baseline
|
Change of FACIT-F score on day 15 compared to baseline after chemotherapy
|
Day 15 compared to baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of FACIT-F score
Time Frame: Day 29 compared to day 15
|
Change of FACIT-F score on day 29 compared to day 15 after chemotherapy
|
Day 29 compared to day 15
|
Change of ESAS
Time Frame: Day 15 compared to baseline
|
Change of ESAS on day 15 compared to baseline after chemotherapy
|
Day 15 compared to baseline
|
Change of ESAS
Time Frame: Day 29 compared to day 15
|
Change of ESAS on day 29 compared to day 15 after chemotherapy
|
Day 29 compared to day 15
|
Incidence of treatment-related adverse events
Time Frame: Day 15 and 29
|
Safety and tolerability assessments
|
Day 15 and 29
|
Exploratory biomarker studies - Urine malondialdehyde - ALDH2 polymorphism (ALDH2 *1/*2, rs671 A/G) - Change of inflammatory cytokines
Time Frame: Day 1, 15 and 29
|
Analysis Inflammatory cytokine and metabolites during ALDH enzyme supplement and explore predictive biomarker using urine malondialdehyde
|
Day 1, 15 and 29
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Soohyeon Lee, MD, PhD, Korea University Anam Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 25, 2021
Primary Completion (Anticipated)
August 31, 2022
Study Completion (Anticipated)
December 31, 2022
Study Registration Dates
First Submitted
August 9, 2021
First Submitted That Met QC Criteria
August 25, 2021
First Posted (Actual)
September 1, 2021
Study Record Updates
Last Update Posted (Actual)
January 11, 2022
Last Update Submitted That Met QC Criteria
December 24, 2021
Last Verified
December 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PicoEnTech001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatigue
-
Bakulev Scientific Center of Cardiovascular SurgeryFoundation for the Support of Physical Culture and Sports BECOME A CHAMPION; Autonomous Non-Profit organization of additional education sports school BECOME A CHAMPIONNot yet recruitingEfficacy, Self | Fatigue, Mental | Fatigue; Muscle, Heart | Fatigue; CombatRussian Federation
-
Universita di VeronaUniversity of Southern CaliforniaCompletedDiet, Healthy | Fasting | Fatigue, Mental | Fatigue; Muscle, HeartItaly
-
University of ZurichRecruitingVocal FatigueSwitzerland
-
KU LeuvenCompleted
-
Société des Produits Nestlé (SPN)Maastricht University Medical CenterCompleted
-
University of Applied Sciences for Health Professions...University of Wisconsin, MilwaukeeCompleted
-
Taoyuan General HospitalCompleted
-
Alaa Yousri Mahmoud AtiaUnknownMuscle FatigueEgypt
-
University Hospital, Clermont-FerrandLaboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques...CompletedNeuromuscular FatigueFrance
-
Central Hospital, Nancy, FranceUniversity of Lorraine; Institut National de Recherche et de Sécurité, Nancy...Unknown
Clinical Trials on ALDH enzyme supplementation
-
AldagenUnknownStroke | Ischemic Stroke | Stroke in Middle Cerebral Artery (MCA)United States
-
AldagenCompletedPeripheral Arterial Disease | Peripheral Vascular Disease | Critical Limb IschemiaUnited States
-
Université de SherbrookeUnknownSystolic Heart Failure | Sub-clinical HypothyroidismCanada
-
Maastricht University Medical CenterBioActor B.V.Recruiting
-
University of Missouri-ColumbiaAlmond Board of CaliforniaRecruiting
-
Charite University, Berlin, GermanyFreie Universität Berlin, Institute of Biology/Genetic, Berlin,Germany; Karl-Franzens-Universität...CompletedSubjective Cognitive DeclineGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)CompletedEsophagitis | Mucositis | Malignant NeoplasmUnited States
-
University of Alabama at BirminghamChildren's Health System, AlabamaActive, not recruitingPremature InfantUnited States
-
Seoul St. Mary's HospitalCompletedProtein-Energy MalnutritionKorea, Republic of
-
University of LeipzigCompleted